Accuray Incorporated (NASDAQ:ARAY) has been given an average rating of “Hold” by the eight research firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $5.48.
A number of brokerages have recently commented on ARAY. BTIG Research reissued a “hold” rating on shares of Accuray in a research report on Wednesday, August 22nd. Citigroup decreased their price objective on shares of Accuray from $4.00 to $3.50 and set a “sell” rating for the company in a research report on Friday, August 17th. BidaskClub downgraded shares of Accuray from a “sell” rating to a “strong sell” rating in a research report on Friday, August 17th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price objective on shares of Accuray in a research report on Friday, August 17th.
In other news, CEO Joshua Levine sold 17,242 shares of the firm’s stock in a transaction dated Wednesday, October 3rd. The shares were sold at an average price of $4.38, for a total transaction of $75,519.96. Following the completion of the sale, the chief executive officer now owns 1,387,162 shares in the company, valued at approximately $6,075,769.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Shigeyuki Hamamatsu sold 8,762 shares of the firm’s stock in a transaction dated Tuesday, October 2nd. The stock was sold at an average price of $4.48, for a total transaction of $39,253.76. Following the sale, the chief financial officer now owns 116,238 shares of the company’s stock, valued at approximately $520,746.24. The disclosure for this sale can be found here. In the last three months, insiders sold 48,378 shares of company stock valued at $218,502. Insiders own 3.40% of the company’s stock.
Accuray stock traded up $0.04 during mid-day trading on Thursday, reaching $4.10. The company’s stock had a trading volume of 917,742 shares, compared to its average volume of 704,044. Accuray has a 12 month low of $3.20 and a 12 month high of $6.15. The company has a market cap of $355.31 million, a P/E ratio of -14.64 and a beta of 1.60. The company has a current ratio of 1.69, a quick ratio of 0.96 and a debt-to-equity ratio of 2.74.
Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Tuesday, October 30th. The medical equipment provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Accuray had a negative net margin of 5.79% and a negative return on equity of 42.24%. The firm had revenue of $95.83 million during the quarter, compared to the consensus estimate of $95.10 million. During the same period last year, the business earned ($0.11) EPS. On average, equities research analysts forecast that Accuray will post -0.14 EPS for the current year.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Recommended Story: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.